Wuxi NextCode programs $75m series B

Temasek has co-led a $75m funding round for genomics company Wuxi NextCode that also attracted biopharmaceutical company Amgen.

Wuxi NextCode, a US-based contract genomics company, raised a $75m series B round co-led by Singapore government-owned investment firm Temasek and private equity firm Yunfeng Capital on Monday.

Amgen Ventures, the corporate venturing arm of biopharmaceutical company Amgen, and private equity firm 3W Partners also contributed to the round.

Wuxi NextCode operates a contract genomics platform that offers features such as sequencing, secondary analysis, storage, interpretation and scalable analytics.

The company was founded as NextCode Health in 2013 but was rebranded two years later when open-access pharmaceutical platform provider Wuxi AppTec purchased a majority stake.

In 2013, Polaris Partners and Arch Venture Partners supplied $15m in series A funding.

Hannes Smarason, chief executive of WuXi NextCode, said: "We are building the world's leading genomic data platform, applying genome sequencing data at scale to improve human health and wellness around the world.

"Our rapidly expanding business is serving the world's leading precision medicine initiatives as well as genome-driven diagnostics and wellness enterprises worldwide."

See more from this Government Report: Singapore


Copyright Mawsonia Limited 2010. Please don't cut articles from www.globalgovernmentventuring.com or the PDF and redistribute by email or post to the web without written permission.